Proceedings of the American Thoracic Society Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

The Proceedings of the American Thoracic Society 3:461-465 (2006)
© 2006 The American Thoracic Society
doi: 10.1513/pats.200603-029MS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Celli, B. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Celli, B. R.

Roger S. Mitchell Lecture. Chronic Obstructive Pulmonary Disease Phenotypes and Their Clinical Relevance

Bartolome R. Celli

Caritas–St. Elizabeth's Medical Center; and Tufts University, Boston, Massachusetts

Correspondence and requests for reprints should be addressed to Bartolome R. Celli, M.D., Pulmonary and Critical Care Services, Caritas St. Elizabeth's Medical Center, 736 Cambridge Street, Boston, MA 02135. E-mail: bcelli{at}copdnet.org

ABSTRACT

Phenotype is defined as the outward physical manifestation of patients with chronic obstructive pulmonary disease (COPD); anything that is part of their observable structure, function, or behavior. As such, for patients with COPD, the time has come to move from a disease expressed solely by the degree of airflow limitation, to a much broader and resourceful characterization of COPD. Recent advances in the detection of specific clinical phenotypes, such as persistent hypoxemia, hyperinflation with inhomogeneous emphysema, frequent exacerbators, and patients with peripheral muscle dysfunction, are resulting in specific forms of approaches to include therapy that are affecting outcomes. Further, the investigation of the differential influence of gender on the development of COPD is finally catching our attention. In the area of basic science, we are beginning to understand different expressions of disease through genomics, proteomics, and metabonomics. Extensions of these findings and that of neglected aspects that may explain the clinical course of certain patients, such as their psychologic background, will certainly increase our understanding and provide more solid scientific rationale to the phenotypic characterization of patients with COPD. Further, such understanding will not only help explain the manifestations and course of the disease in particular patients but also help select for specific therapies. The hope is that, coupled with primary and secondary prevention, we can reverse the current epidemic and we can improve the well-being of patients affected by COPD.

Chronic obstructive pulmonary disease (COPD) has recently been redefined (1) as a preventable and treatable disease state characterized by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases, primarily caused by cigarette smoking. Although COPD affects the lungs, it also produces significant systemic consequences. From this definition, it follows that airflow limitation, best characterized by the FEV1, provides the underpinning of any phenotypic expression of the disease and that the presence of inflammation and systemic consequences are intrinsic important components of the disease that ought to be measured and characterized when describing patients with COPD.

The word "phenotype" needs to be defined. For this article, "phenotype" is defined as "the outward physical manifestation of patients with COPD; anything that is part of their observable structure, function, or behavior." This provides a framework upon which to group what we can document as particular characteristics of patients with COPD.

AIRFLOW LIMITATION: THE DEFINING ELEMENT

The well-known work from Fletcher and coworkers (2) has dominated our way of defining the progression of COPD. Once people begin smoking, and if they are susceptible, their FEV1 declines, and symptoms of breathlessness, cough, and phlegm develop. This landmark study helped develop the field because it provided clinicians and researchers with a practical framework to classify the disease and test interventions. Indeed, the spirometric staging of COPD has proved useful in predicting health status (3), use of health care resources (4), development of exacerbations (5, 6), and mortality (7). Unfortunately, the strict direct association between the rate of decline of FEV1 and disease progression has placed undue constraints on different approaches to understand and to develop and test novel therapies. FEV1 is a valued diagnostic tool, but it is hard to modify when, by definition, we exclude patients with reversibility (1, 8). Within the domain of airflow limitation, it was already evident that the presence of bronchial hyperreactivity conferred a phenotypic expression that was associated with worsened lung function. However, it has become increasingly clear that FEV1 and its change do not fully represent the complex clinical manifestations of COPD (9, 10). The presence of emphysema and hyperinflation (11, 12), the increasingly important role of malnutrition (13), peripheral muscle dysfunction (14), and dyspnea (15) (the dominating symptom in COPD) reflect independent predictors of outcome. Finally, the sex and degree of comorbidity are defining phenotypic characteristics not described and poorly correlated with FEV1. This article summarizes the evidence and support for these phenotypes and their clinical implications. A representation of the currently accepted phenotypic expressions of COPD is shown in Figure 1.


Figure 1
View larger version (15K):
[in this window]
[in a new window]
  		Figure 1. Nonproportional Venn diagram summarizes some of the recognized pathophysiologic processes responsible for the airflow limitation (discontinuous lines) that defines chronic obstructive pulmonary disease. Solid circles represent phenotypic expressions of the disease that are related to outcomes. These phenotypic expressions, although related to airflow limitation, convey independent predictive information and are amenable to specific therapy.

 
EMPHYSEMA AND HYPERINFLATION

Emphysema is defined pathologically as the presence of permanent enlargement of the airspaces distal to the terminal bronchioles, accompanied by destruction of their walls and without obvious fibrosis (1, 2). Therefore, a clinical "phenotype" for emphysema has to depend on methods other than pathology. First, it relies on the physiologic expressions of progressive emphysema. The loss of lung elastic recoil and development of expiratory flow limitation promote progressive air trapping with increase in the end-expiratory lung volume and decrease of the inspiratory capacity (IC). The static lung hyperinflation (LH) and its increase during exercise (dynamic hyperinflation) have been associated with limitations in the functional capacity of those patients (16, 17). Patients with emphysema also have decreased diffusion capacity, which is easily measured using the single-breath carbon monoxide (DLCO) method. In addition, the advent of computed lung tomography (CT) with appropriate new analytic algorithms has provided the field with an excellent tool to investigate the severity, extension, and distribution of the lung destruction. An integration of physiologic data (low DLCO and FEV1) with CT-generated information (homogenous distribution of emphysema) helped select individuals at high risk for death in the National Emphysema Therapy Trial (18). Furthermore, the use of CT and another physiologic test, the work capacity measured during a cardiopulmonary exercise test expressed in watts, was capable of selecting patients whose survival, exercise capacity, and health status improved after lung volume reduction surgery (11). In a recent publication, Casanova and coworkers (12) extended the observations relating hyperinflation to outcome. In a cohort of 629 patients, the IC/TLC ratio predicted respiratory and all-cause mortality better than FEV1. It would be interesting to investigate the possible association between the inspiratory fraction or IC/TLC and the degree of emphysema as determined by CT scan to more objectively relate "emphysema" with "hyperinflation." Independent of the degree of obstruction, the presence of hyperinflation, degree, and distribution of emphysema selects for a "phenotype" of patients for whom at least surgical and nonsurgical volume reduction seems to offer concrete therapeutic alternatives.

SYSTEMIC INVOLVEMENT AND INFLAMMATION

It has been clearly established that some patients with COPD develop extrapulmonary manifestations (1), most of which are poorly related to the degree of airflow limitation. The earliest and best investigated is the development of important hypoxemia. Its presence was noted to confer a very poor prognosis, but, more importantly, its correction when lower than 55 mm Hg was associated with improved survival (19, 20). This observation is important as we look to the future because these landmark trials demonstrate that it is not necessary to alter the rate of decline of FEV1 to modify the natural course of the disease.

The observation that malnutrition as measured by the body mass index (BMI) was an independent predictor of death in patients with COPD (13), subsequently proven to be relatively frequent in less selected population and cohort studies (21), opened the gates to the possible presence of systemic consequences of COPD through mechanisms that have yet to be fully explored. Whether the consequence of inflammation as suggested by the presence of elevated levels of serum tumor necrosis factor {alpha} (TNF-{alpha}) (22), imbalance in oxidants/antioxidants (23), increased work of breathing, or a combination of these mechanisms, low BMI (< 0.21) is clearly a "phenotype" that needs to be recognized.

Similarly, it has long been recognized that most patients with COPD have limitation of their exercise capacity. Although the reason for this was originally thought to be impaired respiratory mechanics, the evidence supports the development of peripheral muscle dysfunction (24, 25), which may have an inflammatory basis (26). This topic, developed in more depth in subsequent chapters in this symposium, has important clinical implications. Poor exercise capacity, whether determined during a cardiopulmonary exercise test using the peak oxygen uptake (peak VO2) (27) or by the simple timed walk test (28), is an excellent independent predictor of survival in these patients. It is possible that therapies aimed at preventing this problem, reversing it if present or even simple exercise training, could have profound impact on outcome.

Clinicians and researchers have associated the diagnosis of COPD with the progressive development of erythrocytosis and its consequences. Although this was perhaps the case in the past, recent evidence points to the frequent presence of anemia in 10 to 20% of patients with COPD (29). The cause of the anemia remains debatable. However, the evidence points to anemia of chronic diseases with its inflammatory nature. Furthermore, in the preliminary study recently reported by Cote and colleagues (29), the degree of anemia correlated with mortality independent of the degree of comorbidity.

The critical issue is whether the systemic manifestations of COPD could result from the "spillage" of inflammatory cytokines or activated cells, which then hone in on certain organs. In favor of this mechanism is the observation that levels of serum C-reactive protein, interleukin 6 (IL-6), leukotriene B4, TNF-{alpha}, and other biomarkers are elevated in patients with COPD (30–33). If so, it may be possible to unravel these pathways and target specific molecules to prevent or reverse their pathogenic potential.

SEX

Several recent studies have suggested sex differences in the diagnosis and clinical manifestations of COPD (34). Women are less responsive to long-term exercise therapy (35), score lower in quality-of-life questionnaires, manifest more reactive airways (36), and report more dyspnea for the same degree of airflow obstruction (35) than men. In a recent report, DeTorres and colleagues (37) showed that in patients attending a pulmonary clinic for COPD (GOLD [Global Initiative for Chronic Obstructive Lung Disease] stages II and III), women had smoked less, were younger, and had less comorbidity scores than men. For the same lung function, they had better oxygenation. However, women had more exacerbations, expressed more dyspnea, and had worse scores in all the domains of the quality-of-life questionnaires. These results indicate that more attention must be devoted to the characterization of the way in which exposure to inhaled particles (from cigarette or from biomass fuels) affect women.

EXACERBATION FREQUENCY

The cost of COPD is staggering, reaching $31.9 billion annually in the United States alone. Most of this is due to recurrent acute exacerbations that lead to emergency visits and hospitalizations. During an exacerbation, patients with COPD present to the clinician with worsened dyspnea, cough, phlegm production, or change in the color of previously produced phlegm, which may result in respiratory failure. After episodes of acute exacerbation, the patients report substantially decreased scores in their perception of health status (38) and, if admitted with respiratory failure, mortality at 1 yr can be as high as 50%. Several reports from the East London cohort (39, 40) have indicated that patients with similar degree of airflow limitation, caused by bacteria, viruses, or environmental factors, may have different rates of exacerbations, with a minority of the patients presenting with more than two exacerbations per year (frequent exacerbators). Not only do these patients score worse in health status questionnaires but they also have a faster rate of decline of FEV1 (40). Little is known about what distinguishes frequent versus infrequent exacerbators. We do know that in stable patients with COPD, the systemic expression of the inflammation is suggested by studies showing increased plasma levels of biomarkers. There is also evidence of local respiratory inflammation measured by exhaled condensate (41). During exacerbation, there are changes observed in sputum, where increases in the level of IL-6, IL-8, and TNF-{alpha} suggest an intense inflammatory burst (41). Presumably, the circulating level of these cytokines could also change during an exacerbation, representing a systemic involvement of an initial respiratory event. However, there are no studies providing conclusive evidence of this mechanism. One fact is clear: Elucidation of the mechanisms responsible for the frequent-exacerbator phenotype must be undertaken so that we can develop appropriate therapeutic strategies.

MULTIDIMENSIONAL ASSESSMENT

FEV1 fails to adequately represent all of the respiratory and systemic manifestations of the disease. For example, FEV1 correlates weakly with dyspnea (20), and the change in FEV1 has been shown to have different characteristics from the rate of decline of health status in at least one drug trial (42). Prospective observational studies of patients with COPD have found that dyspnea and health status scores predict mortality better than FEV1. Thus, although FEV1 is important to obtain and essential in the staging of any patient with COPD, the addition of other variables provide useful information to more comprehensively help evaluate patients with COPD. The potential variables should correlate independently with prognosis in COPD, should be easily measurable, and should serve as surrogate for other potentially important variables. In a recent report, the multidimensional index that includes BMI (B), degree of airflow obstruction (O), dyspnea score (D), and exercise endurance measured with the 6-min-walk distance (E) (BODE index), was a better predictor of mortality than FEV1 (43). The incorporation of various phenotypic elements into one integrative scoring system is of practical advantage because it allows us to group patients according to their prognosis. In addition, the BODE index could provide a surrogate tool to determine outcome because all four components of the index can potentially be improved by therapy.

CLINICAL IMPLICATIONS

The degree of airflow remains the defining characteristic of COPD and thus its most important phenotypic expression. However, there is sufficient evidence to support the need to consider several phenotypic expressions in the characterization of patients with COPD (Table 1). These include the degree, type, and distribution of emphysema and its physiologic expressions as measured by DLCO; the degree of hyperinflation expressed by the IC and the IC/TLC; the presence of abnormal gas exchange (hypoxia and hypercapnia); the presence of systemic involvement as measured by the BMI; the exercise capacity, whether measured in the laboratory (peak oxygen uptake) or in the field (6-min walk test); and the degree of functional dyspnea. They can practically be integrated into multidimensional tools, such as the BODE index, which are capable of providing a more comprehensive evaluation of the patients. Finally, the overall impact of the disease on patient perception can be integrated by measuring the health-related quality of life. The determination of these phenotypic characteristics is not only scientifically interesting but is also clinically important because they confer prognostic value and, more importantly, they determine response to therapy. Oxygen for hypoxemic patients, noninvasive mechanical ventilation in patients with hypercapnic respiratory failure and acidosis, lung volume reduction in patients with upper lobe disease, and poor exercise capacity have shown to decrease mortality. In addition, pulmonary rehabilitation has improved outcome in symptomatic patients with decreased exercise capacity, whereas nutrition optimization has had an impact on mortality.


View this table:
[in this window]
[in a new window]
  		TABLE 1. PHENOTYPES AND AVAILABLE TREATMENTS

 
FUTURE DIRECTIONS

The moment has come to move from a disease expressed solely by the degree of airflow limitation that it generates to a much broader and resourceful characterization of COPD. Recent advances in the application of basic science resources to the understanding of clinical expressions of disease through genomics, proteomics, and metabonomics, or neglected aspects that may explain the clinical course of certain patients, such as their psychologic background and milieu, will increase our understanding and provide a more solid scientific rationale to the phenotypic characterization of patients with COPD (Table 2). Such understanding will not only help explain the manifestations and course of the disease in particular patients but also help select for specific therapies. The hope is that, coupled with primary and secondary prevention, we can reverse the current epidemic and improve the well-being of patients affected by COPD. The future is bright.


View this table:
[in this window]
[in a new window]
  		TABLE 2. OTHER POSSIBLE PHENOTYPE CHARACTERIZERS

 
FOOTNOTES

Conflict of Interest Statement: B.R.C. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript.

(Received in original form March 15, 2006; accepted in final form April 17, 2006)

REFERENCES

  1. Celli BR, MacNee W. Standards for the diagnosis and treatment of COPD. Eur Respir J 2004;23:932–946.[Free Full Text]
  2. Fletcher C, Tinker C, Speizer F, Peto R. Natural course of emphysema and chronic bronchitis. London: Oxford University Press; 1976.
  3. Ferrer M, Alonso J, Morera J, et al. Chronic obstructive pulmonary disease and health related quality of life. Ann Intern Med 1997;127:1072–1079.[Abstract/Free Full Text]
  4. Friedman M, Serby C, Menjoge S, Wilson J, Hilleman D, Witek T. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999;115:635–641.[Abstract/Free Full Text]
  5. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297–1303.[Abstract/Free Full Text]
  6. Dewan N, Rafique S, Kanwar B, et al. Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest 2000;117:662–671.[Abstract/Free Full Text]
  7. Anthonisen NR, Wright EC, Hodgkin JE. The IPPB Trial Group. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986;133:14–20.[Medline]
  8. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. The GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163:1256–1276.[Free Full Text]
  9. Celli BR. Monitoring the progression of chronic obstructive pulmonary disease: time for a new staging system. Eur Respir Rev 1999;9:67,165–168.
  10. Agustí AGN, Noguera A, Sauleda J, Sala E, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003;21:347–360.[Abstract/Free Full Text]
  11. National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003;348:2059–2073.[Abstract/Free Full Text]
  12. Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, Celli BR. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:591–597.[Abstract/Free Full Text]
  13. Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1791–1797.[Abstract/Free Full Text]
  14. Maltais F, LeBlanc P, Jobin J, et al. Intensity of training and physiologic adaptation in patient with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997;155:555–561.[Abstract]
  15. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002;121:1434–1440.[Abstract/Free Full Text]
  16. Diaz O, Villafranca C, Ghezzo H, Borzone G, Leiva A, Milic-Emil J, Lisboa C. Role of inspiratory capacity on exercise tolerance in COPD patients with and without expiratory flow limitation at rest. Eur Respir J 2000;16:269–275.[Abstract]
  17. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:770–777.[Abstract/Free Full Text]
  18. National Emphysema Treatment Trial Research Group. Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med 2001;345:1075–1083.[Abstract/Free Full Text]
  19. Report of the Medical Research Council Working Party. Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981;1:681–685.[CrossRef][Medline]
  20. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. Ann Intern Med 1980;93:391–398.[CrossRef][Medline]
  21. Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:1856–1861.[Abstract/Free Full Text]
  22. Di Francia M, Barbier D, Mege JL, Orehek J. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994;150:1453–1455.[Abstract]
  23. Rodriguez-Roisin R, MacNee W. Pathophysiology of chronic obstructive pulmonary disease. Eur Respir Monographs 1998;3:107–126.
  24. Saey D, Debigare R, LeBlanc P, et al. Contractile leg fatigue after cycle exercise: a factor limiting exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;168:425–430.[Abstract/Free Full Text]
  25. Decramer M, Gosselink R, Troosters T, Verschueren M, Evers G. Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J 1997;10:417–423.[Abstract]
  26. Agusti AG, Sauleda J, Miralles C, et al. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:485–489.[Abstract/Free Full Text]
  27. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 2002;167:544–549.[CrossRef][Medline]
  28. Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR. The 6–minute walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J 2004;28:28–33.
  29. Cote C, Zilberberg M, Mody S, Celli B. Anemia is a predictor of mortality in patients with COPD [abstract]. Proc Am Thorac Soc 2005;2:A890.
  30. Schols AMWJ, Buurman WA, Staal-van den Brekel AJ, Dentener MA, Wouters EFM. Evidence for a relation between metabolic derangement and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 1996;51:819–824.[Abstract/Free Full Text]
  31. Rahman I, Morrison D, Donaldson K, MacNee W. Systemic oxidative stress in asthma, COPD and smokers. Am J Respir Crit Care Med 1996;154:1055–1060.[Abstract]
  32. Vernooy JH, Kucukaycan M, Jacobs JA, Chavannes NH, Buurman WA, Dentener MA, Wooters EF. Local and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:1218–1224.[Abstract/Free Full Text]
  33. Noguera A, Busquets X, Sauleda J, Villaverde JM, MacNee W, Agusti A. Expression of adhesion molecules and G proteins in circulating neutrophils in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158:1664–1668.[Abstract/Free Full Text]
  34. Soriano JB, Maier WC, Egger P, Visick G, Thakrar B, Sykes J, Pride NB. Recent trends in physician diagnosed COPD in women and men in the UK. Thorax 2000;55:789–794.[Abstract/Free Full Text]
  35. Foy CG, Rejeski J, Berry MJ, Zaccaro D, Woodard M. Gender moderates the effects of exercise therapy on health- related quality of life among COPD patients. Chest 2001;119:70–76.[Abstract/Free Full Text]
  36. Kanner RE, Connet JE, Murray DA, Buist S, Lee WW, Tashkin DP, Wise R; Lung Health Study. Gender difference in airway hyperresponsiveness in smokers with mild COPD. Am J Respir Crit Care Med 1994;150:956–961.[Abstract]
  37. de Torres JP, Casanova C, Hernández C, Abreu J, Aguirre-Jaime A, Celli B. Gender and chronic obstructive pulmonary disease in patients attending a pulmonary clinic. Chest 2005;128:20012–20016.
  38. Seemungal TAR, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418–1422.[Medline]
  39. Seemungal TAR, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608–1613.[Abstract/Free Full Text]
  40. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care 2003;48:1204–1213.[Medline]
  41. Bhowmik A, Seemungal TAR, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55:114–120.[Abstract/Free Full Text]
  42. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297–1303.[Abstract/Free Full Text]
  43. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body mass index, airflow obstruction, dyspnea and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005–1012.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Eur Respir JHome page
D. A. Lomas, E. K. Silverman, L. D. Edwards, N. W. Locantore, B. E. Miller, D. H. Horstman, R. Tal-Singer, and on behalf of the Evaluation of COPD Longitudinally
Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD
Eur. Respir. J., July 1, 2009; 34(1): 95 - 102.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
M. Remy-Jardin and J. Remy
Vascular Disease in Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, December 15, 2008; 5(9): 891 - 899.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
S E Marsh, J Travers, M Weatherall, M V Williams, S Aldington, P M Shirtcliffe, A L Hansell, M R Nowitz, A A McNaughton, J B Soriano, et al.
Proportional classifications of COPD phenotypes
Thorax, September 1, 2008; 63(9): 761 - 767.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
I Sabroe, L C Parker, P M A Calverley, S K Dower, and M K B Whyte
Pathological networking: a new approach to understanding COPD
Postgrad. Med. J., May 1, 2008; 84(991): 259 - 264.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
I. Sabroe, L. C Parker, P. M A Calverley, S. K Dower, and M. K B Whyte
Pathological networking: a new approach to understanding COPD
Thorax, August 1, 2007; 62(8): 733 - 738.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. T. Dransfield, G. R. Washko, M. G. Foreman, R. S. J. Estepar, J. Reilly, and W. C. Bailey
Gender Differences in the Severity of CT Emphysema in COPD
Chest, August 1, 2007; 132(2): 464 - 470.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
T. Yoshida and R. M. Tuder
Pathobiology of Cigarette Smoke-Induced Chronic Obstructive Pulmonary Disease
Physiol Rev, July 1, 2007; 87(3): 1047 - 1082.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Celli, B. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Celli, B. R.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS